In vitro effects of the toll-like receptor agonists monophosphoryl lipid A and CpG-rich oligonucleotides on cytokine production by equine cells.
Authors: Ziegler A, Gerber V, Marti E
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary Insect bite hypersensitivity remains a frustrating condition to manage, with allergen-specific immunotherapy largely unsuccessful in horses despite showing promise in other species. Ziegler and colleagues investigated whether toll-like receptor agonists could be harnessed as vaccine adjuvants to reorient the immune response away from the allergy-prone Th2 pathway towards Th1 and regulatory pathways, using an in vitro model of peripheral blood mononuclear cells from both healthy and affected horses exposed to Culicoides allergens. Monophosphoryl lipid A (MPLA) demonstrated the most promising immunomodulatory profile, consistently promoting IL-10 secretion whilst suppressing the allergen-induced production of interferon-γ, IL-4 and IL-17 regardless of disease status; conversely, CpG-rich oligodeoxynucleotides (CpG-ODN) markedly increased interferon responses but failed to suppress Th2 cytokine production. For IBH management, MPLA emerges as a viable adjuvant candidate that could enhance the efficacy of future immunotherapeutic protocols by actively promoting immune tolerance, whilst CpG-ODN may find better application in vaccine development for infectious or neoplastic conditions where robust interferon responses are therapeutically advantageous. These findings provide a rational scientific basis for moving MPLA-adjuvanted allergen vaccines into clinical trials in IBH-affected horses.
Read the full abstract on PubMed
Practical Takeaways
- •MPLA may improve efficacy of IBH immunotherapy by promoting regulatory immune responses rather than Th2-dominant allergy responses
- •CpG-ODN is not recommended as an adjuvant for IBH vaccines but could be useful for infectious disease or neoplastic disease vaccines in horses
- •These findings suggest tailored immunomodulatory approaches based on TLR agonist choice could optimize vaccine efficacy for different equine disease categories
Key Findings
- •MPLA induced IL-10 secretion in all horses regardless of antigen presence while suppressing IFN-γ, IL-4 and IL-17 production, promoting a regulatory immune response
- •CpG-ODN significantly increased IFN-α, IFN-γ and IL-4 production but had little effect on IL-10, making it unsuitable for allergic disease immunotherapy
- •MPLA shows promise as a vaccine adjuvant for allergen-specific immunotherapy in IBH due to its shift towards Th1/regulatory immune responses